Asset 3xxxhdpi

Our mission is to create, develop and protect new products and technologies that have the potential to significantly improve patients' lives.

Innovation

Our products are designed to improve modern day practice.

UP TO DATE PRESS RELEASES

See Below

ANTIVIRALS

Read Here

Woman-owned Palisades Therapeutics in collaboration with the Veterans Medical Research Foundation is granted FDA clearance to begin Phase II/III COVID-outpatient oral therapeutic study that targets >80% of patients

Read Here

PALISADES THERAPEUTICS ANNOUNCES A NEWLY PATENTED NOVEL APPROACH THAT COULD BE KEY TO STOPPING COVID AND OTHER VIRUSES

Read Here

A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection

Read Here

Palisades Therapeutics’ Proprietary Dual Action Compound Reduces COVID-19 Viral Entry and Inflammatory Responses

Read Here

Palisades Therapeutics PT150 for treatment of “long haul COVID” neuro-psychiatric conditions

Read Here

Palisades Therapeutics pioneers new therapeutic for rare disease Parechovirus.

Read Here

PT150 for treatment of “Long Haul COVID” featured poster at the neuroscience clinical-translational research symposium. 

NEURODEGENERATION

Read Here

Palisades Therapeutics Drug Platform Demonstrates Reduction in Neuroinflammation Across Three Species

Read Here

Palisades Therapeutics’ Clinical Stage Drug PT150 Granted Patent for Parkinson’s Disease and Multiple Sclerosis

ONCOLOGY

Read Here

Pan-cancer analysis to identify a novel class of glucocorticoid and androgen receptor antagonists with potent anti-tumor activity.

Read Here

Palisades Therapeutics Targets the IHOP Protein as a Biomarker to Detect Pancreatic Cancer and Enable PT Therapeutic

Read Here

Palisades Therapeutics Announces New Anti-Cancer Drug-PT162, a p53-Reactivating Cell Cycle Checkpoint Inhibitor

AGRICULTURE

Read Here

Proprietary Dual Action Compound Could Save the Citrus Industry from Citrus Greening Plague

Read Here

Eradicating Citrus Greening By Dual Action Targeting of Liberibacter asiaticus and Diaphorina citri

ADDICTIONS

Read Here

Pill to pill communication provides prescription compliance, drug delivery, safety and sampling of gut bacteria. 

Read Here

The current study investigated whether the stress hormone receptor antagonist, PT150, would block the rewarding properties of ethanol via the glucocorticoid receptor system and attenuate other ethanol-induced effects.

"The most brilliant ideas are the ones that make you consider why we haven't always done it this way."

About Us

BUSINESS MODEL

We out-license or sell our products and intellectual property to third parties for global commercialization. Our companies have a unique paradigm. We consist of leading scientists, physicians, clinicians, lawyers and professionals working together without salary to change the world.

This site was created to keep industry insiders aware of our progress in the areas of Diagnostics, Therapeutics and Devices.

________
Click Image To Learn More!

Poster featured at the 2021 California Citrus Conference

Combined Antibiotic And Glucocorticoid Antagonism As A Method For Disrupting The Citrus Greening Life Cycle

Anthony R Arment, PhD1, Eric W Triplett, PhD2, Cody Artzner2, Neil D Theise, MD3
1 Central State University, 2University of Florida, 3Palisades Therapeutics

Our Innovations

Why Choose Us!​

Reliable Team of Experts and Innovators

Every product is backed by our incredible group of industry experts consisting of physicians, scientists and much more.

Fully Covered Intellectual Property

We have gathered an incredible team of intellectual property lawyers to help fully protect our products all over the world.

Diverse Portfolio of Programs

Our team designs and looks to generate compelling proof of concept data for each program to facilitate global commercialization by a partner/acquirer.

Our Collaborators